Potential use of recombinant human thyrotropin in the treatment of distant metastases in patients with differentiated thyroid cancer.
暂无分享,去创建一个
J. Jonklaas | M. Mete | D. van Nostrand | K. Burman | L. Wartofsky | J. Klubo-Gwiezdzinska | D. Van Nostrand
[1] S. Larson,et al. Recombinant Human TSH-Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence. , 2012 .
[2] M. Mete,et al. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in the Identification of Metastasis in Differentiated Thyroid Cancer with 131I Planar Whole-Body Imaging and 124I PET , 2012, The Journal of Nuclear Medicine.
[3] J. Jonklaas,et al. Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. , 2012, Thyroid : official journal of the American Thyroid Association.
[4] M. Dietlein,et al. Recombinant human TSH increases uptake and effective half-life of radioiodine in thyroid hormone secreting metastases of follicular thyroid cancer. , 2012, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[5] J. Jonklaas,et al. Age modifies the response to recombinant human thyrotropin. , 2010, Thyroid : official journal of the American Thyroid Association.
[6] P. Rosário,et al. Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients. , 2010, Thyroid : official journal of the American Thyroid Association.
[7] T. Heusner,et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: 124I PET/CT dosimetric comparisons , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[8] S. Larson,et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. , 2010, Thyroid : official journal of the American Thyroid Association.
[9] S. Vethakkan,et al. Sudden onset of haemoptysis and hypoxia after recombinant human thyroid‐stimulating hormone use in a patient with papillary thyroid carcinoma and pulmonary metastases , 2009, Internal medicine journal.
[10] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[11] L. Ghiadoni,et al. Enhanced proatherogenic inflammation after recombinant human TSH administration in patients monitored for thyroid cancer remnant , 2009, Clinical endocrinology.
[12] G. Paz-Filho,et al. Recombinant human thyrotropin in the management of thyroid disorders , 2008 .
[13] M. Mussap,et al. Absence of thyrotropin-induced increase in leptin levels in patients with history of differentiated thyroid carcinoma undergoing recombinant human thyrotropin testing , 2008, Journal of endocrinological investigation.
[14] M. Schlumberger,et al. 131I Effective Half-Life and Dosimetry in Thyroid Cancer Patients , 2008, Journal of Nuclear Medicine.
[15] L. Duntas,et al. Review on the occasion of a decade of recombinant human TSH: prospects and novel uses. , 2008, Thyroid : official journal of the American Thyroid Association.
[16] S. Larson,et al. Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008, Journal of Nuclear Medicine.
[17] D. Rubello,et al. Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. , 2007, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[18] E. Hindié,et al. Stimulation test in the follow-up of thyroid cancer: Plasma rhTSH levels are dependent on body weight, not endogenously stimulated TSH values , 2007, Nuclear medicine communications.
[19] A. Driedger,et al. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. , 2006, Thyroid : official journal of the American Thyroid Association.
[20] G. Karanikas,et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients , 2006, Clinical endocrinology.
[21] Markus Luster,et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] A. Sorisky,et al. Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. , 2005, Obesity research.
[23] M. Luster,et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. , 2005, Endocrine-related cancer.
[24] O. Mundler,et al. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. , 2004, Thyroid : official journal of the American Thyroid Association.
[25] Michael R. Tuttle,et al. Near-lethal respiratory failure after recombinant human thyroid-stimulating hormone use in a patient with metastatic thyroid carcinoma. , 2003, Thyroid : official journal of the American Thyroid Association.
[26] R. Dierckx,et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[27] K. Bohuslavizki,et al. Value of recombinant human thyrotropin in high-dose radioiodine therapy: a case report. , 2002, Journal of nuclear medicine technology.
[28] S. Larson,et al. Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. , 2000, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.
[29] D. Van Roost,et al. Recombinant human thyrotropin in thyroid cancer and hypopituitarism due to sella metastasis. , 1999, Thyroid : official journal of the American Thyroid Association.
[30] A. F. Stewart,et al. Papillary thyroid carcinoma metastatic to the pituitary gland. , 1999, Thyroid : official journal of the American Thyroid Association.
[31] B. Weintraub,et al. Development and in vitro characterization of human recombinant thyrotropin. , 1999, Thyroid : official journal of the American Thyroid Association.
[32] J. Garber,et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. , 1997, The New England journal of medicine.
[33] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[34] L. Duntas,et al. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. , 2007, European journal of endocrinology.
[35] A. Pinchera,et al. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. , 2001, European journal of endocrinology.
[36] B. Weintraub,et al. Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. , 1991, Endocrinology.